Editorial: Adding evolocumab to statin therapy can benefit patients with peripheral arterial disease and claudication

Cardiovasc Revasc Med. 2023 Oct:55:57. doi: 10.1016/j.carrev.2023.06.008. Epub 2023 Jun 10.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Peripheral Arterial Disease* / diagnosis
  • Peripheral Arterial Disease* / drug therapy

Substances

  • evolocumab
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents